Amici Capital’s Regulus Therapeutics RGLS Stock Holding History

Amici Capital’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-688	Closed	-$272K	–	82
2016 Q3	$272K	Hold	688	–	–	0.07%	82
2016 Q2	$238K	Buy	688 +334	+94%	+$239K	0.04%	110
2016 Q1	$295K	Buy	+354	New	+$282K	0.03%	98
2015 Q4	–	Sell	-625	Closed	-$491K	–	126
2015 Q3	$491K	Hold	625	–	–	0.02%	127
2015 Q2	$822K	Buy	+625	New	+$1.01M	0.03%	115

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SDIC

South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Amici Capital's RGLS Position: Q4 2016 in Review

Amici Capital sold out of Regulus Therapeutics (RGLS) in Q4 2016, closing a stake of 688 shares — an estimated $272K sold.

Amici Capital first reported a position in RGLS in Q2 2015 and held it in 5 quarters. The position peaked at $822K in Q2 2015. 68 funds tracked by Wall St. Rank hold RGLS as of Q4 2016.

Amici Capital reported no remaining Regulus Therapeutics position as of Q4 2016 after selling out during the quarter.
Amici Capital sold 688 Regulus Therapeutics shares in Q4 2016, an estimated $272K.
Amici Capital first reported a position in Regulus Therapeutics in Q2 2015 and held it in 5 quarters.
Amici Capital's Regulus Therapeutics position peaked at $822K in Q2 2015.
68 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2016.

Based on Amici Capital's 13F filing for Q4 2016, filed 14 Feb 2017.